Lexicon and Cetek Enter Natural Products Drug Screening and Technology Agreement
News Apr 28, 2006
Lexicon Genetics Incorporated and Cetek Corporation have announced an agreement under which Cetek will provide Lexicon with a library derived from natural products for use by Lexicon in drug discovery.
Cetek will also utilize its natural products chemistry technologies and chemical biology and scale-up capabilities to isolate and identify compounds with activity against targets screened by Lexicon.
Under the agreement, Lexicon will screen Cetek's premier natural products library, containing 50,000 samples, against a specified number of targets selected by Lexicon from among those discovered and analyzed in its Genome5000™ program.
In this program, Lexicon is using its gene knockout technology to discover the physiological functions of 5,000 potential drug targets.
Compounds contained in Cetek's library that show activity against selected targets may be licensed by Lexicon for drug discovery and development.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.